Market revenue in 2023 | USD 480,215.1 million |
Market revenue in 2030 | USD 1,144,370.4 million |
Growth rate | 13.2% (CAGR from 2023 to 2030) |
Largest segment | Health |
Fastest growing segment | Bioinformatics |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Health, Food & Agriculture, Natural reseources & Environment, Industrial Processing, Bioinformatics, Others Applications |
Key market players worldwide | AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biotechnology market will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 44.43% in 2023. Horizon Databook has segmented the Europe biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
Europe has witnessed several developments in the field of stem cell research, cell therapy, personalized medicine, biopharmaceutical development, and proteomics. This is because of several initiatives undertaken by the government and nongovernment organizations for development of biotechnology sector in the region.
For instance, the Personalized Medicine 2020 and Beyond initiative included 14 countries and 27 organizations across Europe to enhance research in the area of personalized medicine. In addition, EMA supported the Innovative Medicine Initiative (IMI-2) project to enhance pharmaceutical research in Europe. The project is expected to be completed by 2024.
Similarly, the European Prospective Investigation into Cancer and Nutrition (EPIC) involves 10 countries across Europe to carry out biomarker and genetic investigations for 15 years. The ERA-Net on rare diseases project (E-Rare-3) involves 25 institutions located across 17 non-European, Europe associated, and European countries to study cell- and gene-drug therapy for rare disorders.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biotechnology market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account